Webinar: Ask the expert with Professor Marcela Votruba
Join us for our upcoming webinar!
Search
Search results
Fundraising
Raise money to help support people affected by inherited sight loss to lead better lives today and accelerate the search for treatments for the future.
e-Newsletter December 2025
Our monthly e-Newsletter featuring the latest updates from Retina UK.
ProQR clinical trial for Leber’s Congenital Amourosis (LCA) 10
Biopharmaceutical company ProQR is conducting a Phase 2/3 clinical trial (Illuminate) to measure the safety and effectiveness of RNA therapy, Sepofarsen which aims to treat Leber's Congenital Amourosis (LCA) 10.
Fundraising FAQs
Fancy fundraising for Retina UK? Here’s a few pointers to help get you started.
Frequently asked questions
The following questions are often asked by people contacting Retina UK.
Why genes matter
Genes exist inside all the cells that make up your body. They contain genetic code (DNA) and provide instructions for constructing proteins, which are the building blocks of our bodies and perform a huge variety of roles.
Meira GTx announces positive data from phase clinical trial
Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.
Positive early findings from ProQR trial of USH2A therapy
Biotechnology company ProQR has announced encouraging results from its early analysis of the phase 1/2 trial of QR-421a, an innovative approach to treating sight loss caused by mutations in a particular section of the USH2A gene.
Webinar: Usher syndrome mini series – part two
Professor Mariya Moosajee looks at the latest research, clinical trials and treatment prospects for people affected by Usher’s syndrome.